Drug Profile
AUS 131
Alternative Names: AUS-131; S-equolLatest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Ausio Pharmaceuticals
- Developer Ausio Pharmaceuticals; University of Kansas Medical Center; University of Texas Health Science Center at San Antonio
- Class Antidementias; Antineoplastics; Isoflavones; Small molecules
- Mechanism of Action Estrogen receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Benign prostatic hyperplasia; Vasomotor symptoms
- Phase I/II Alzheimer's disease
- No development reported Osteoporosis; Triple negative breast cancer
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-0 development in Breast-cancer(First-line therapy) in USA (PO, Tablet)
- 09 Jun 2020 AUS 131 is still in phase-0 development in Triple negative Breast-cancer(First-line therapy) in USA (PO, Tablet) (NCT02352025)
- 29 May 2020 Efficacy and adverse events data from a phase 0 trial in Breast cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)